Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank M Balis

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|May 12, 2009
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumorsHolly J Meany, Katherine E Warren, Elizabeth Fox, et al.
Pediatric Blood & Cancer|August 11, 2006
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group StudyPeter C Adamson, Katherine K Matthay, Michelle O'Brien, et al.
DNA and Cell Biology|August 30, 2019
Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical CarcinomaJoseph H Oved, Ashley Graul, Robert A Burger, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2014
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastomaAmi V Desai, Elizabeth Fox, L Mary Smith, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2015
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumorsElizabeth Fox, Brigitte C Widemann, Devang Pastakia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576Manish Agrawal, Jame Abraham, Frank M Balis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumorsKatherine E Warren, Alberta A Aikin, Madeleine Libucha, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Cancer Chemotherapy and Pharmacology|February 11, 2025
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysisFrank M Balis, Elizabeth Rieger, Nancy J Bunin, et al.
Journal of the National Cancer Institute|May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpointHolly Meany, Frank M Balis, Alberta Aikin, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|May 12, 2009
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumorsHolly J Meany, Katherine E Warren, Elizabeth Fox, et al.
Pediatric Blood & Cancer|August 11, 2006
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group StudyPeter C Adamson, Katherine K Matthay, Michelle O'Brien, et al.
DNA and Cell Biology|August 30, 2019
Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical CarcinomaJoseph H Oved, Ashley Graul, Robert A Burger, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2014
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastomaAmi V Desai, Elizabeth Fox, L Mary Smith, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2015
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumorsElizabeth Fox, Brigitte C Widemann, Devang Pastakia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576Manish Agrawal, Jame Abraham, Frank M Balis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumorsKatherine E Warren, Alberta A Aikin, Madeleine Libucha, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Cancer Chemotherapy and Pharmacology|February 11, 2025
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysisFrank M Balis, Elizabeth Rieger, Nancy J Bunin, et al.
Journal of the National Cancer Institute|May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpointHolly Meany, Frank M Balis, Alberta Aikin, et al.
Pageof 10